Table 1. Baseline characteristics of study population.
| Variable | N (%) or median [interquartile range] | |
|---|---|---|
| Sex-ratio (n = 145) | Women | 29.7% |
| Age | Years | 52 [48:55] |
| CDCa clinical stage (n = 144) | A | 52.1% |
| B | 25.0% | |
| C | 22.9% | |
| Duration of HIV infection (n = 144) | Years | 21.9 [17.5:26.6] |
| ART (n = 145) | Yes | 91.7% |
| HIV viral load (n = 145) | <20 copies/mL | 74.5% |
| if detectable | copies/mL | 306 [54:12100] |
| CD4 T cells count (n = 144) | cells/μL | 468 [317:634] |
| <350 cells/μL | Yes | 29.2% |
| HCV genotype (n = 112) | 1 | 56.3% |
| 2 | 2.7% | |
| 3 | 25.0% | |
| 4 | 16.1% | |
| HCV viral load (n = 138) | copies/mL | 188721 [0:1885000] |
| Type of HCV infection (n = 145) | Chronic infection | 82.8% |
| Spontaneously resolved | 15.2% | |
| Acute | 2.1% | |
| Outcome after anti-HCV therapy (n = 145) | Sustained VR b | 47.7% |
| Partial VR | 6.2% | |
| Relapse | 13.8% | |
| No response | 20.0% | |
| Discontinued treatment | 7.7% | |
| In treatment | 4.6% | |
| Not applicable (not treated) | 55% | |
| HBV co-infection (n = 145) | Yes | 12.4% |
| METAVIR score | (Only if chronic: n = 120) | |
| Assessment method (n = 113) | Liver biopsy | 20.4% |
| Fibroscan® | 77.9% | |
| Actitest-Fibrotest® | 1.8% | |
| Score (n = 137) | F0 or F1 | 54.5% |
| F2 | 16.1% | |
| F3 | 11.6% | |
| F4 | 17.9% | |
| Plasma 16S rDNA (n = 145) | copies/μL | 9.17f (7.79:10.8) |
| Plasma LBPc (n = 132) | μg/mL | 17.0f (15.5:18.6) |
| Plasma sCD14d(n = 132) | ng/mL | 1901.7 [1573.2:2232.8] |
| Plasma I-FABPe (n = 132) | pg/mL | 478.3f (412.5:554.5) |
aCenters for Disease Control and Prevention.
bVirologic response
cLipopolysaccharide (LPS)-binding protein
dsoluble CD14
e intestinal fatty acid binding protein
fGeometric mean (95% IC)